- Previous Close
6.43 - Open
6.30 - Bid 6.12 x 100
- Ask 6.80 x 100
- Day's Range
6.41 - 6.41 - 52 Week Range
5.18 - 7.82 - Volume
285 - Avg. Volume
192,353 - Market Cap (intraday)
281.343M - Beta (5Y Monthly) --
- PE Ratio (TTM)
213.67 - EPS (TTM)
0.03 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. It offers SARS-CoV-2 antigen rapid and SARS-CoV-2/influenza A/B antigen rapid tests; and lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, chemiluminescence immunoassay, and reverse-transcription polymerase chain reaction products. It serves over-the-counter, point-of-care testing, and laboratory markets. The company was incorporated in 2021 and is based in Frankfurt am Main, Germany.
www.anbio.comRecent News: NNNN
View MorePerformance Overview: NNNN
Trailing total returns as of 4/15/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NNNN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NNNN
View MoreValuation Measures
Market Cap
281.34M
Enterprise Value
271.03M
Trailing P/E
213.03
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
97.07
Price/Book (mrq)
15.28
Enterprise Value/Revenue
28.52
Enterprise Value/EBITDA
61.12
Financial Highlights
Profitability and Income Statement
Profit Margin
45.57%
Return on Assets (ttm)
15.05%
Return on Equity (ttm)
26.64%
Revenue (ttm)
9.5M
Net Income Avi to Common (ttm)
4.33M
Diluted EPS (ttm)
0.03
Balance Sheet and Cash Flow
Total Cash (mrq)
10.31M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-2.09M